Triple

Target class: disease-modifying therapy for spinal muscular atrophy
Context triple: [risdiplam, instanceOf, disease-modifying therapy for spinal muscular atrophy]

• A. disease-modifying therapy chosen
  A disease-modifying therapy is a treatment that alters the underlying course or mechanisms of a disease to slow its progression, reduce long-term damage, or change its overall outcome rather than just alleviating symptoms.
• B. multiple sclerosis therapy
  Multiple sclerosis therapy encompasses medical, rehabilitative, and lifestyle interventions aimed at modifying disease activity, managing symptoms, and preserving function and quality of life in individuals with multiple sclerosis.
• C. multiple sclerosis medication
  A multiple sclerosis medication is a drug or therapeutic agent designed to modify the disease course, manage relapses, or alleviate symptoms in individuals with multiple sclerosis by targeting immune or neurological processes.
• D. antisense oligonucleotide
  An antisense oligonucleotide is a short, synthetic strand of nucleic acid designed to bind specifically to a target RNA sequence and modulate its function, typically to alter gene expression for therapeutic purposes.
• E. Bruton tyrosine kinase inhibitor
  A Bruton tyrosine kinase inhibitor is a targeted small-molecule drug that blocks BTK signaling in B cells to disrupt pathways critical for their activation, proliferation, and survival, primarily used in the treatment of certain B-cell malignancies and autoimmune diseases.
• F. None of above.